ScholarIQanswers from OpenAlex
Sarah Cannon
InstitutionResearch output, impact & collaborations
Sarah Cannon is a institution indexed in ScholarIQ from OpenAlex.
What is known about Sarah Cannon?
ScholarIQrecord summary
Sarah Cannon is a research organisation in Nashville, US. OpenAlex records 7,270 works and 623,476 citations for it. 882 researchers list it as their most recent affiliation.
How many works does Sarah Cannon have?
ScholarIQindexed works
Sarah Cannon has 7,270 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sarah Cannon have?
ScholarIQcitation count
Sarah Cannon has 623,476 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Sarah Cannon?
ScholarIQresearcher count
Sarah Cannon has 882 researchers in the ScholarIQ index.
What is the average h-index at Sarah Cannon?
ScholarIQavg h-index
Sarah Cannon has an average h-index of 86.8 in OpenAlex.
What is the ROR of Sarah Cannon?
ScholarIQror
The ROR for Sarah Cannon is on the source record.
What is the OpenAlex record for Sarah Cannon?
ScholarIQopenalex
The OpenAlex for Sarah Cannon is on the source record.
Who are the most-cited researchers behind Sarah Cannon?
ScholarIQtop researchers by citations
What are the most-cited papers on Sarah Cannon?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher
How much of the research on Sarah Cannon is open access?
ScholarIQopen access share
83%OPEN ACCESS